A step towards characterisation of electrophysiological profile of torsadogenic drugs

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 3, 2011, Pages 269-278

  Champeroux, Pascal ^a   Ouillé, Aude ^b   Martel, Eric ^a   Fowler, John Sinclair Lawrence ^a   Maurin, Anne ^a   Richard, Serge ^a   Le Guennec, Jean Yves ^b  

^a CERB   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Electrocardiogram; Patch clamp; Purkinje fibres; QT prolongation; Safety pharmacology; Telemetry

Indexed keywords

DILTIAZEM; DOFETILIDE; ISOPRENALINE; MOXIFLOXACIN; NICARDIPINE; PHENYTOIN; POTASSIUM CHANNEL HERG; PROPRANOLOL; QUINIDINE; RISPERIDONE; SOTALOL; TERFENADINE; THIORIDAZINE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EMBRYO; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; GENETIC TRANSFECTION; HEART RATE VARIABILITY; HEART REPOLARIZATION; HOMEOSTASIS; HUMAN; HUMAN CELL; ION CURRENT; MALE; NONHUMAN; PARASYMPATHETIC TONE; PATCH CLAMP; PURKINJE FIBER MEMBRANE POTENTIAL; QT PROLONGATION; SPECIES DIFFERENCE; SYMPATHETIC TONE; TELEMETRY;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELL LINE; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PURKINJE FIBERS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TELEMETRY; TORSADES DE POINTES; TRANSFECTION;

CANIS FAMILIARIS; MACACA FASCICULARIS;

EID: 79954572843     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.01.001     Document Type: Article

References (54)

1. Abi-Gerges N., Small B.G., Lawrence C.L., Hammond T.G., Valentin J.P., Pollard C.E. Gender differences in the slow delayed (IKs) but not in inward (IK1) rectifier K+ currents of canine Purkinje fibre cardiac action potential: Key roles for IKs, beta-adrenoceptor stimulation, pacing rate and gender. British Journal of Pharmacology 2006, 147:653-660.
2. Abbott G.W., Goldstein S.A. Disease-associated mutations in KCNE potassium channel subunits (MIRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. The FASEB Journal 2002, 16:390-400.
3. Alexandrou A.J., Duncan R.S., Sullivan A., Hancox J.C., Leishman D.J., Witchel H.J., et al. Mechanism of hERG K+ channel blockade by the fluoroquinilone antibiotic moxifloxacin. British Journal of Pharmacology 2006, 147:905-916.
4. Antzelevitch C., Sun Z.Q., Zhang Z.Q., Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. Journal of the American College of Cardiology 1996, 28:1836-1848.
5. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005, 2:9-15.
6. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007, 9:4-15.
7. Aubert M., Osterwalder R., Wagner B., Parrilla I., Cavero I., Doessegger L., et al. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans. Drug Safety 2006, 29:237-254.
8. Ben Caref E., Boutjdir M., Himel H.D., El-Sherif N. Role of subendocardial Purkinje network in triggering torsade de pointes arrhythmia in experimental long QT syndrome. Europace 2008, 10:1218-1223.
9. Burashnikov A., Antzelevitch C. Block of I(Ks) does not induce early afterdepolarization activity but promotes beta-adrenergic agonist-induced delayed afterdepolarization activity. Journal of Cardiovascular Electrophysiology 2000, 11:458-465.
10. Burashnikov A., Antzelevitch C. Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. Journal of Cardiovascular Electrophysiology 2002, 13:172-177.
11. Calaghan S.C., Le Guennec J.Y., White E. Modulation of Ca(2+) signaling by microtubule disruption in rat ventricular myocytes and its dependence on the ruptured patch-clamp configuration. Circulation Research 2001, 88:32-37.
12. Champeroux P., Viaud K., El Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., et al. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. British Journal of Pharmacology 2005, 144:376-385.
13. Champeroux P., Martel E., Fowler J.S., Maurin A., Sola M.L., Jude S., et al. Calculation of QT shift in non clinical safety pharmacology studies. Journal of Pharmacological and Toxicological Methods 2009, 59:73-85.
14. Champeroux P., Ouillé A., Martel E., Fowler J.S., Maurin A., Jude S., et al. Interferences of the autonomic nervous system with drug induced QT prolongation: A point to consider in non-clinical safety studies. Journal of Pharmacological and Toxicological Methods 2010, 61:251-263.
15. Chen L., Marquardt M.L., Tester D.J., Sampson K.J., Ackerman M.J., Kass R.S. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20,990-20,995.
16. Chouabe C., Drici M.D., Romey G., Barhanin J., Lazdunski M. HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Molecular Pharmacology 1998, 54:695-703.
17. Chouabe C., Drici M.D., Romey G., Barhanin J. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Thérapie 2000, 55:195-202.
18. Crumb W.J., Ekins S., Sarazan R.D., Wikel J.H., Wrighton S.A., Carlson C., et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharmaceutical Research 2006, 23:1133-1143.
19. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
20. Daleau P., Lessard E., Groleau M.F., Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995, 91:3010-3016.
21. Danielsson B.R., Lansdell K., Patmore L., Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Research 2005, 63:17-25.
22. De Ponti F., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce Torsade de pointes: An overview. Drug Safety 2002, 25:263-286.
23. Duggal P., Vesely M.R., Wattanasirichaigoon D., Villafane J., Kaushik V., Beggs A.H. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. Circulation 1998, 97:142-146.
24. Gao Z., Sun H., Chiu S.W., Lau C.P., Li G.R. Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. British Journal of Pharmacology 2005, 144:595-604.
25. Haushalter T.M., Friedrichs G.S., Reynolds D.L., Barecki-Roach M., Pastino G., Hayes R., et al. The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. British Journal of Pharmacology 2008, 154:1457-1464.
26. Hayashi S., Kii Y., Tabo M., Fukuda H., Itoh T., Shimosato T., et al. QT PRODACT: A multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. Journal of Pharmacological Sciences 2005, 99:423-437.
27. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal of Pharmacological Toxicological Methods 2007, 55:159-175.
28. Huang Z., Shi G., Gao F., Zhang Y., Liu X., Christopher T.A., et al. Effects of N-n-butyl haloperidol iodide on L-type calcium channels and intracellular free calcium in rat ventricular myocytes. Biochemistry and Cell Biology 2007, 85:182-188.
29. Johannessen M., Ramachandran S., Riemer L., Ramos-Serrano A., Ruoho A.E., Jackson M.B. Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous systems. American Journal of Physiology. Cell Physiology 2009, 296:1049-1057.
30. Jost N., Virág L., Bitay M., Takács J., Lengyel C., Biliczki P., et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 2005, 112:1392-1399.
31. Kirsch G.E., Trepakova E.S., Brimecombe J.C., Sidach S.S., Erickson H.D., Kochan M.C., et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. Journal of Pharmacological and Toxicological Methods 2004, 50:93-101.
32. Kobayashi T., Washiyama K., Ikeda K. Modulators of G protein-activated inwardly rectifying K+ channels: Potentially therapeutic agents for addictive drug users. Annals of the New York Academy of Sciences 2004, 1025:590-594.
33. Koidl B., Miyawaki N., Tritthart H.A. A novel benzothiazine Ca2+ channel antagonist, semotiadil, inhibits cardiac L-type Ca2+ currents. European Journal of Pharmacology 1997, 322:243-247.
34. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., et al. Benchmarking safety pharmacology regulatory packages and best practices. Journal of Pharmacological and Toxicological Methods 2008, 58:99-109.
35. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. Journal of Cardiovascular Pharmacology 2004, 43:369-379.
36. Medeiros-Domingo A., Kaku T., Tester D.J., Iturralde-Torres P., Itty A., Ye B., et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007, 116:134-142.
37. Napier L.D., Stanfill A., Yoshishige D.A., Jackson K.E., Borron B.A., Caffrey J.L. Autonomic control of heart rate in dogs treated chronically with morphine. The American Journal of Physiology 1998, 44:2199-2210.
38. Park K.S., Kong I.D., Park K.C., Lee J.W. Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Medical Journal 1999, 40:144-151.
39. Pascarel C., Hongo K., Cazorla O., White E., Le Guennec J.Y. Different effects of gadolinium on I(KR), I(KS) and I(K1) in guinea-pig isolated ventricular myocytes. British Journal of Pharmacology 1998, 124:356-360.
40. Rajamani S., Eckhardt L.L., Valdivia C.R., Klemens C.A., Gillman B.M., Anderson C.L., et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. British Journal of Pharmacology 2006, 149:481-489.
41. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
42. Rubio L.S., Garrido G., Llanes L., Alvarez J.L. Effects of tetrandrine on Ca(2+)- and Na(+)-currents of single bullfrog cardiomyocytes. Journal of Molecular and Cellular Cardiology 1993, 25:801-813.
43. Sanguinetti M.C., Curran M.E., Zou A., Shen J., Spector P.S., Atkinson D.L., et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996, 384:80-83.
44. Schneider J., Hauser R., Andreas J.O., Linz K., Jahnel U. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. European Journal of Pharmacology 2005, 512:53-60.
45. Shimizu W., Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. Journal of the American College of Cardiology 2000, 35:778-786.
46. Stanat S.J., Carlton C.G., Crumb W.J., Agrawal K.C., Clarkson C.W. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Molecular and Cellular Biochemistry 2003, 254:1-7.
47. Tawil R., Ptacek L.J., Pavlakis S.G., DeVivo D.C., Penn A.S., Ozdemir C., et al. Andersen's syndrome: Potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Annals of Neurology 1994, 35:326-330.
48. Towart R., Linders J.T., Hermans A.N., Rochbacher J., Van der Linde H.J., Ercken M., et al. Blockade of the I(Ks) potassium channel: An overlooked cardiovascular liability in drug safety screening?. Journal of Pharmacological and Toxicological Methods 2009, 60:1-10.
49. Tristani-Firouzi M., Jensen J.L., Donaldson M.R., Sansone V., Meola G., Hahn A., et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). The Journal of Clinical Investigation 2002, 110:381-388.
50. Vomberge T., Hoffmann M., Himmel H. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. Journal of Pharmacological and Toxicological Methods 2006, 54:130-140.
51. Ks to canine ventricular repolarization: Key role for beta-adrenergic receptor stimulation. Circulation 2003, 107:2753-2760.
52. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J.L., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
53. Wang Q., Curran M.E., Splawski I., Burn T.C., Millholland J.M., VanRaay T.J., et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 1996, 12:245-250.
54. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophysical Journal 1998, 74:230-241.